Your browser doesn't support javascript.
BBIBP-CorV/Sinopharm COVID-19 vaccine-induced humoral response in frontline workers
BBIBP-CorV/Sinopharma |COVID-19 |immunoglobulin G |neutralizing antibodies |SARS-CoV-2 |vaccines ; 2022(Boletin de Malariologia y Salud Ambiental)
Article in Spanish | WHO COVID | ID: covidwho-1995048
ABSTRACT
With the arrival of the vaccine against COVID-19, the decrease in cases of SARS-CoV-2 infection was evidenced. The objective of the study was to quantify the production of neutralizing antibodies (An) and immunoglobulin G (S-IgG) in frontline workers immunized with two doses of the BBIBP-CorV/Sinopharma vaccine. A cross-sectional analytical observational study was carried out in health personnel immunized with the inactivated vaccine (BBIBP-CorV). Their blood samples were collected three months after the second dose, to measure antibody responses (An, S-IgG). Of a total of 172 people evaluated, 110 (64%) people already had COVID-19 before entering the study, An titers were greater than 10 AU/mL in 60.5% of those vaccinated and 89, 3% showed S-IgG greater than 50 AU/mL. Workers older than 60 years were the group that did not develop enough antibodies. The correlation of An and S-IgG was positive (r=0.84) (p<0.001). The administration of two doses of the inactivated BBIBP-CorV/Sinopharma vaccine caused a notable An and S-IgG response, except in those over 60 years of age. © 2022 Instituto de Altos Estudios de Salud Publica. All rights reserved.
Full text: Available Collection: Databases of international organizations Database: WHO COVID Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: Spanish Journal: Sinopharma |COVID-19 |immunoglobulin G |neutralizing antibodies |SARS-CoV-2 |vaccines Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Databases of international organizations Database: WHO COVID Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: Spanish Journal: Sinopharma |COVID-19 |immunoglobulin G |neutralizing antibodies |SARS-CoV-2 |vaccines Document Type: Article